Eli Lilly bowel disease treatment succeeds in late-stage study

March 16 - Eli Lilly and Co LLY.N said on Tuesday its experimental treatment for an inflammatory bowel disease succeeded in a late-stage trial.

The drug, mirikizumab, met the main goal of showing reduced bowel urgency in moderate to severe ulcerative colitis.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Shailesh Kuber)

((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325;))